Peptides - Metabolic
Mazdutide
Triple agonist (GLP-1/GIP/glucagon) similar to retatrutide for comprehensive metabolic support
Dosage
3-9mg weekly
Results
8-12 weeks
Frequency
Weekly
Cost
$250-450/month
Estimated monthly
$250-450
Administration
Method
Subcutaneous injection
Timing
AM
Food
Any time
Key Benefits
- Triple receptor activity
- Significant weight loss
- Improved glycemic control
- Enhanced metabolic health
- Liver fat reduction
Stacks Well With
Important Considerations
- • MEN2
- • Thyroid cancer history
- • Pancreatitis
- • Pregnancy
Additional Notes
- • Similar to retatrutide
- • Triple agonist mechanism
- • Chinese pharma development
Research & Studies
Mazdutide: Triple-Agonist for Obesity Phase 3
2024·Clinical Trial
Mazdutide: GLP-1/GIP/Glucagon Receptor Agonist
2023·Clinical Trial
Research provided for educational purposes. Always consult a healthcare provider.